Goldberg Jenna D, Zheng Junting, Ratan Ravin, Small Trudy N, Lai Kuan-Chi, Boulad Farid, Castro-Malaspina Hugo, Giralt Sergio A, Jakubowski Ann A, Kernan Nancy A, O'Reilly Richard J, Papadopoulos Esperanza B, Young James W, van den Brink Marcel R M, Heller Glenn, Perales Miguel-Angel
a Department of Medicine , Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center , New York , NY , USA.
b Department of Medicine , Weill Cornell Medical College , New York , NY , USA.
Leuk Lymphoma. 2017 Aug;58(8):1859-1871. doi: 10.1080/10428194.2016.1265113. Epub 2017 Jan 10.
Infection, relapse, and GVHD can complicate allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although the effect of poor immune recovery on infection risk is well-established, there are limited data on the effect of immune reconstitution on relapse and survival, especially following T-cell depletion (TCD). To characterize the pattern of immune reconstitution in the first year after transplant and its effects on survival and relapse, we performed a retrospective study in 375 recipients of a myeloablative TCD allo-HSCT for hematologic malignancies. We noted that different subsets recover sequentially, CD8 + T cells first, followed by total CD4 + and naïve CD4 + T cells, indicating thymic recovery during the first year after HSCT. In the multivariate model, a fully HLA-matched donor and recovery of T-cell function, assessed by PHA response at 6 months, were the only factors independently associated with OS and EFS. In conclusion, T-cell recovery is an important predictor of outcome after TCD allo-HSCT.
感染、复发和移植物抗宿主病(GVHD)会使异基因造血干细胞移植(allo-HSCT)变得复杂。虽然免疫恢复不良对感染风险的影响已得到充分证实,但关于免疫重建对复发和生存的影响的数据有限,尤其是在进行T细胞清除(TCD)之后。为了描述移植后第一年免疫重建的模式及其对生存和复发的影响,我们对375例接受清髓性TCD allo-HSCT治疗血液系统恶性肿瘤的受者进行了一项回顾性研究。我们注意到不同亚群依次恢复,首先是CD8 + T细胞,然后是总CD4 + T细胞和幼稚CD4 + T细胞,这表明HSCT后第一年胸腺功能恢复。在多变量模型中,完全HLA匹配的供体和通过6个月时PHA反应评估的T细胞功能恢复是与总生存期(OS)和无事件生存期(EFS)独立相关的唯一因素。总之,T细胞恢复是TCD allo-HSCT后预后的重要预测指标。